Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

State Street SPDR S&P Biotech ETF (NY:XBI)

123.50 -3.05 (-2.41%)

Official Closing Price Updated: 6:30 PM EST, Mar 3, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	13,501,422
Open	123.56
Bid (Size)	123.57 (200)
Ask (Size)	124.00 (600)
Prev. Close	126.55
Today's Range	121.98 - 125.30
52wk Range	66.66 - 132.09
Shares Outstanding	541,500
Dividend Yield	1.32%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Why Did NTLA Stock Jump 10% In Pre-Market Today? ↗

March 02, 2026

The company announced that the U.S. FDA lifted a clinical hold on its Phase 3 trial of ATTR-CM treatment drug.

Via Stocktwits

Why Did QURE Stock Almost Halve Pre-Market Today? ↗

March 02, 2026

uniQure said the FDA does not agree that Phase I/II data are sufficient to serve as primary evidence of effectiveness for a marketing application for its Huntington’s disease gene therapy, AMT-130.

Via Stocktwits

Performance

YTD	+1.6%	+1.6%
1 Month	-3.0%	-3.0%
3 Month	+4.3%	+4.3%
6 Month	+33.0%	+33.0%
1 Year	+44.3%	+44.3%

More News

AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction ↗

February 26, 2026

Via Stocktwits

IBRX Stock Rises Pre-Market After ANKTIVA Combo Shows Stronger Bladder Cancer Responses In Phase 2 Trial ↗

February 26, 2026

Via Stocktwits

CLDX Soars On Bullish Timelines For Urticaria Clinical Program: Retail Sees Experimental Skin Treatment’s Sales Beat Big Pharma’s Dupixent ↗

February 25, 2026

Via Stocktwits

RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ ↗

February 25, 2026

Via Stocktwits

Novavax Q4 Earnings Preview: Wall Street Expects Wider Losses Amid Diversification Efforts ↗

February 24, 2026

Via Stocktwits

Why Did PVLA Stock Surge 45% In Pre-Market Today? ↗

February 24, 2026

Via Stocktwits

RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder ↗

February 23, 2026

Via Stocktwits

ImmunityBio Inks Partnerships To Launch Cancer Drug In Saudi Arabia Amid Expansion Efforts ↗

February 20, 2026

Via Stocktwits

ARDX Stock Is Down Pre-Market After Q4 Earnings Miss, So Why Did This Firm Just Hike Price Target By 80%? ↗

February 20, 2026

Via Stocktwits

GRAL Stock Slumps After Hours As Trial For Cancer Test Fails To Show Reduction In Late-Stage Diagnoses ↗

February 19, 2026

Via Stocktwits

ARDX Stock Slips After Hours As Q4 Earnings Disappoint: Retail Sees Ibsrela Driving Outperformance In Time ↗

February 19, 2026

Via Stocktwits

ImmunityBio Announces Partnership To Expand Access To Anktiva Across 30 Countries ↗

February 19, 2026

Via Stocktwits

SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition ↗

February 18, 2026

Via Stocktwits

IBRX Gains 30% On Fresh Approval For Bladder Cancer Drug In EU: Retail, Wall Street Eyes Further Rally ↗

February 18, 2026

Via Stocktwits

IBRX Stock Jumps 6% Pre-Market On BCG Update In Saudi Arabia – Retail Says Share Price Is ‘Attractive’ ↗

February 17, 2026

Via Stocktwits

IBRX Stokes Retail Chatter — Investors See Anktiva Beat Merck’s Keytruda With Approval In EU ↗

February 13, 2026

Via Stocktwits

RARE Stock Slumps On Multiple Wall Street Price Target Slashes, Clinical Pipeline Uncertainty ↗

February 13, 2026

Via Stocktwits

VKTX Stock Rallies After Hours On Optimism Around Company’s Obesity Pipeline ↗

February 11, 2026

Via Stocktwits

Biotech Beat Nvidia in 2025. Can It Do It Again? ↗

February 11, 2026

Via The Motley Fool

Sector Alert: 4 Healthcare ETFs Poised for Explosive Growth Now ↗

February 11, 2026

Via The Motley Fool

Why Did UPB Stock Pop 20% In Pre-Market Today? ↗

February 11, 2026

Via Stocktwits

Why Did RGNX Shares Plummet 19% After-Hours Today? ↗

February 09, 2026

Via Stocktwits

MDXG Stock Rises As MiMedx Enters Into Exclusive Distribution Agreement For Three Products ↗

February 04, 2026

Via Stocktwits

Frequently Asked Questions

Is State Street SPDR S&P Biotech ETF publicly traded?

Yes, State Street SPDR S&P Biotech ETF is publicly traded.

What exchange does State Street SPDR S&P Biotech ETF trade on?

State Street SPDR S&P Biotech ETF trades on the New York Stock Exchange

What is the ticker symbol for State Street SPDR S&P Biotech ETF?

The ticker symbol for State Street SPDR S&P Biotech ETF is XBI on the New York Stock Exchange

What is the current price of State Street SPDR S&P Biotech ETF?

The current price of State Street SPDR S&P Biotech ETF is 123.50

When was State Street SPDR S&P Biotech ETF last traded?

The last trade of State Street SPDR S&P Biotech ETF was at 03/03/26 06:30 PM ET

What is the market capitalization of State Street SPDR S&P Biotech ETF?

The market capitalization of State Street SPDR S&P Biotech ETF is 66.88M

How many shares of State Street SPDR S&P Biotech ETF are outstanding?

State Street SPDR S&P Biotech ETF has 67M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.